The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Prospective, multi-center, randomized trial. A maximum of 130 patients will be enrolled, in a 2:1 ratio to receive either the JACTAX LD stent or the TAXUS™ Libertè™ stent to evaluate the efficacy of the product.
Condition or disease
Coronary Artery Disease
Device: JACTAX LD DESDevice: TAXUS™ Libertè™ DES
The JACTAX Drug Eluting Stent has been designed to minimize the amount of polymer in contact with the vessel surface, thus potentially reducing the incidence of untoward side effects. The Juxtaposed Ablumenal Coating Process is capable of exclusive coating on the ablumenal side of pre-mounted bare metal stents. Juxtaposed Ablumenal Coating is a proprietary formulation containing a bioerodable polymer. The combination of the Juxtaposed Ablumenal Coating Process and Juxtaposed Ablumenal Coating create a unique microstructure surface, and reduces the amount of required polymer.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
General Inclusion Criteria:
Patient is ≥ 18 years of age
Patient with coronary artery disease, eligible for percutaneous coronary intervention (PCI)
Patient demonstrates a LVEF of ≥ 25%
Patient or legal guardian understands and agrees to comply with all specified study requirements and provides written informed consent to this effect.
Angiographic Inclusion Criteria
Target lesion is de novo native coronary artery lesion (i.e., a coronary lesion not previously treated)
The target lesion can be treated with a maximum of one stent, with adequate coverage onto the healthy tissue, as specified in visual estimate guidelines. Maximum lesion length is 20mm.
The reference vessel diameter is between 2.75mm and 3.5mm
Study lesion diameter stenosis is ≥70% (visual estimate) and <100% and a TIMI flow >1.
Study lesion has been successfully pre-dilated
Patients enrolled for treatment may demonstrate multiple lesions in target vessel. However lesions must be covered completely by one study stent.
Patient must have no more than two lesions requiring treatments. These lesions must be in different vessel distributions. For example, if the target lesion is in the LAD, then the non target lesion must be present in either the circumflex or RCA. The non-study lesion may not be in a branch vessel or distal to the target vessel location.
The non target lesion must be successfully treated prior to the treatment of the target lesion. The non target lesion must be treated with a TAXUS paclitaxel eluting stent or a bare metal stainless steel stent.
General Exclusion Criteria:
The patient has a life expectancy of less than 24 months due to another medical condition
Patient has a history of hypersensitivity to paclitaxel or structurally related compounds
Patient exhibits cardiogenic shock (systolic pressure <80mmHg and PCWP >20mmHg or cardiac index <1.8 liters/minute/m or intra-aortic balloon pump or intravenous inotropes are needed to maintain a systolic pressure >80mmHg) for any time within 24 hours prior to index procedure
Patient demonstrates evidence of acute or chronic renal dysfunction (serum creatinine >2.0 mg/dl or 177 umol/l)
Planned cardiac surgery procedure <= 9 months post index procedure
Patient demonstrates evidence of myocardial infarction (elevated CK, CKMB or Troponin) within 72 hours prior to the index procedure and/or CK >2X local lab's ULN, unless CK-MB is < 2X ULN
Patient exhibits acute ST segment elevation MI within 72 hours prior to the index procedure
CVA including stroke or TIA within previous 3 months
Patient demonstrates evidence of leukopenia
Patient demonstrates evidence of thrombocytopenia or thrombocytosis
Patient is contraindicated to ASA, clopidogrel or ticlopidine
Patient is currently taking warfarin or possibility of treatment with warfarin during the following 6 months post index procedure
Patient has been treated with paclitaxel or other chemotherapeutic agents within 12 months prior to planned index procedure
Anticipated treatment with paclitaxel or oral rapamycin during any period in the 9 months after the index procedure
Patient has received a drug eluting stent within 12 months prior to planned index procedure
Previous or planned treatment with intravascular brachytherapy in target vessel
Known allergy to stainless steel
Male or female with known intention to procreate within 3 months after the index procedure
Female of childbearing potential with a positive pregnancy test within 7 days before the index procedure or lactating or intends to become pregnant during the 9 months post index procedure
Angiographic Exclusion Criteria
Evidence of probable or definite thrombus of the study vessel, based on angiography or IVUS
Study lesion is totally occluded (TIMI flow <= 1)either at baseline or before predilatation
Study lesion or the study vessel proximal to the study lesion is moderately or severely calcified by visual estimate
Study lesion is ostial in location (within 3.0 mm of vessel origin)
Study lesion involving arterial segments with highly tortuous anatomy or where lesion is located within or distal to a > 60 degree bend in the vessel
Study lesion involves a bifurcation with a diseased (>50% stenotic) branch vessel >2.0 mm in diameter
Left main coronary artery disease (stenosis >50%) whether protected or unprotected
Target lesion length >20mm based on visual estimate by operator
Target vessel diameter >3.5mm based on visual estimate by operator
Target vessel diameter <2.75 mm based on visual estimate by operator
Pre-treatment of the target lesion (excluding predilation) with another interventional device